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Although therapeutic angiogenesis by angiogenic cytokines is a feasible strategy to improve regional blood ﬂow in ischemic
regions, the optimal delivery mode needs to be established. Here we designed a complex of collagen matrix (CM) and basic
ﬁbroblast growth factor (bFGF) and evaluated its proangiogenic eﬀect in ischemic hindlimbs. The bFGF-CM was prepared
using lyophilization. The morphology, porosity and toxicity of CM were examined. The bFGF releasing proﬁle and bioactivity
of released bFGF were assessed. bFGF-CM was intramuscularly implanted into the rabbit ischemic hindlimb model. Oxygen
saturation parameters (OSP) of ischemic hindlimbs was measured to evaluate the extremity perfusion at intervals. Histological
examination was performed to evaluate the level of angiogenesis. The CM and bFGF-CM were of identical multiporous structure
lacking cytotoxicity. The releasing proﬁle lasted 10 days and the released bFGF remained bioactive. OSP in bFGF-CM group was
signiﬁcantly higher than that in CM, bFGF and ischemic groups at 2 and 4 weeks. The number of capillaries and mature vessels
in bFGF-CM group were signiﬁcantly greater than that in untreated control, CM and bFGF groups. Therefore, bFGF-CM enables
the safe and eﬀective long-term release of bFGF with improved angiogenesis in ischemic hindlimbs compared with CM devoid of
bFGF.
1.Introduction
Regeneration therapy with angiogenic cytokines has shown
promising results for chronic ischemic hindlimb [1]. Among
the cytokines used, basic ﬁbroblast growth factor (bFGF) has
been shown to be a safe and potentially eﬀective therapy to
reduce lower extremity ischemia either on its own or in con-
junction with bypass surgery or percutaneous catheter-based
recanalization [2, 3]. However, the optimal mode of delivery
of the growth factor remains to be established.
Current angiogenic cytokine therapies to regenerate is-
chemic tissues in the body primarily rely on the bolus
administration of the growth factor or direct injection into
the blood stream [3]. The results of existing studies are
not consistent [4, 5]. The bioactivity of bFGF could rapidly
disappear in solution form or the growth factors could be
rapidly cleared from the tissue [6]. Preclinical trials of direct
administration of angiogenic cytokines have shown some
limitations, whereby bFGF stimulated vessel growth for a
transient period but resulted in fragile and leaky vessels that
were prone to regression. Only the formation of mature
blood vessels can bring about substantial tissue function and
perfusion enhancement [7].
Thus, the exact mode of administration of growth
factors for improving ischemic tissue function and perfusion
remains uncertain and needs further exploration. Previous
results suggest that a long-term controlled release system
is required. In order to explore the most eﬃcient mode2 The Scientiﬁc World Journal
of administration, sustained-release delivery systems using
biodegradable materials into which the growth factor can be
impregnated have been studied. As the biodegradable mate-
rials are degraded, growth factors are gradually released over
time in situ [5, 8–10]. One approach involves the localized,
sustained release of growth factors at the site of ischemia
from biodegradable gelatin microspheres. These micro-
spheres have been shown to be successful in protecting the
cytokines from enzymatic degradation [11–15].
In this study, we developed a multiporous collagen
matrix (CM) to impregnate the bFGF so as to prolong the
release of bFGF from the matrix. We hypothesized that sus-
tained release of bFGF over a long period of time could
improve revascularization and reperfusion in a critical limb
ischemic model.
2.MaterialsandMethods
2.1. Preparation of the CM and the bFGF-CM Complex. The
type I bovine collagen (GIBCO Invitrogen Corp) suspension
containing 2.5% collagen and heparin (50U/mL, Shanghai
First Biochemical and Pharmaceutical, China, 50U/mL) was
prepared. The collagen suspension was centrifuged to re-
move bubbles and was subsequently mixed gently into paste.
To produce the complex of bFGF-CM, 15μg/mL of bFGF
(Sigma) was added to the 2.5% collagen solution. The
collagen solution alone or that containing bFGF was poured
into a frame mold. The samples were frozen at −80◦Ca n d
then lyophilized for 12h to obtain a CM or bFGF-CM.
The samples were sterilized with ethylene oxide gas at
room temperature and stored under vacuum until use. The
porosity of the matrix was measured by the 100% ethanol
liquid replacement method. In order to maintain the bioac-
tivity of bFGF, no crosslinking or other chemical agent was
added. The collagen matrix was mounted on an aluminum
stub, coated with gold using a Sputter Coater, and examined
with a scanning electron microscope (SEM) (Tescan, Czech
Republic).
2.2. Cytotoxicity of the CM. Rabbit bone-marrow-derived
mesenchymal stromal cells (MSCs) were isolated, expanded,
and used to test the cytotoxicity of the CM. The third
passage MSCs were ﬁrst seeded in a 96-well microplate at
a density of 1.0 × 104 cells. Each well contained 200μL
Dulbecco’s modiﬁed Eagle’s medium (DMEM; Invitrogen)
supplemented with 10% fetal bovine serum (FBS) and 1%
penicillin-streptomycin solution at 37◦Ci n5 %C O 2 atmo-
sphere. After 24h of culture, the medium was replaced with
fresh medium containing 200μg/mL of collagen particles,
which had been scraped from the CM. The medium was
replaced every 2 days and MSCs cultured in DMEM were
considered as the control. The cell number was counted with
a hemocytometer at speciﬁc intervals.
2.3. Rehydration Analysis. The dried CM, with a weight of
10 ± 0.1g, was immersed in PBS, and after 24h, samples
were collected. Then, the samples were blotted with tissue to
remove the liquid on the surface. The swelling ratios Rr (%)
of test samples were calculated using the following equation:
(Ws − Wd)/W d,w h e r eWs is the weight of the swollen test
sample and Wd is the weight of the dried test sample.
2.4. Sustained Release Analysis. The bFGF-CM complex was
added to a tube that contained 10mL PBS at 37◦C and shak-
en at 40rpm. At intervals, the PBS was collected for bFGF
analysis and replaced with fresh PBS. bFGF in the collected
solution was determined by the enzyme-linked immunosor-
bent assay, which was performed according to the manufac-
turer’sinstructions(QuantikinehumanbFGFimmunoassay;
R & D Systems, Minneapolis, MN, USA).
2.5. Bioactivity of the Released bFGF. This experiment was
to evaluate the bioactivity of bFGF which was incorporated
into collagen matrix. A total of 15mg of bFGF-CM was cut
intopieces,whichwereaddedtoacentrifugetubecontaining
15mL of DMEM. The tube was then vibrated at 120rpm
at 37◦C. After 1 day of releasing, the tube was centrifuged
and the supernatant was used to analyze bFGF bioactivity.
Rabbit bone-marrow-derived MSCs were isolated, puriﬁed,
and seeded in a 96-well microplate at a density of 1 ×
104 cells per well containing 200μL of culture medium at
37◦Ci na5 %C O 2 atmosphere. After 24h, the medium
was replaced with the release medium supplemented with
10% FBS and 1% penicillin-streptomycin solution. MSCs
cultured in DMEM medium were considered as the control.
The cell number was counted with a hemocytometer at day 2
and day 5.
2.6. Ischemic Hindlimb Model. All experiments that involved
the use of animals were approved by the Institutional Animal
CareandUseCommitteeatXiamenUniversity.NewZealand
Whiterabbitswereanesthetizedwithanintramuscularinjec-
tion of ketamine (30mg/kg) and an intravenous injection
of pentobarbital (30mg/kg) and ventilated with a mixture
of oxygen, nitrogen, and isoﬂurane during the operation.
A longitudinal incision was made on the right hindlimb
and the femoral artery was removed. The incision was then
sutured, all animals were regularly examined and treated
with analgesic and antibiotic drugs for 5 days. The animals
were used for experiments at 10 days after surgery.
2.7. Treatment of Ischemic Hindlimb. The ischemic hindlimb
models were randomly divided into the ischemic, bFGF, CM,
and bFGF-CM groups (n = 5). In the ischemic group, the
animalsdidnotreceiveanytreatment.InthebFGFgroup,on
average 15μg of bFGF in 3mL of PBS was injected into two
sites along the sides of the longitudinal incision, each site was
0.8cm2 in area, and the injection was 1cm in depth. In the
CM group, the CM (0.8cm in diameter) was implanted into
thesamesitesasthatinbFGFgroup.InthebFGF-CMgroup,
the complex of bFGF and CM (0.8cm in diameter) was
implanted into the sites described previously. The implanted
sites were stitched as a marker.
2.8. Oxygen Saturation Parameter Analysis. The hindlimbs of






































































































































































Figure 1: Characterization of the CM and the bFGF-CM complex. (a) Gross overview of the bFGF-CM complex. (b) Scanning electron
microscopy indicated that bFGF-CM had a multiporous structure (bar = 100μm). (c) Proliferation assays showed that CM did not have
a cytotoxic eﬀect on MSCs. (d) Rehydration analysis of the CM. (e) The kinetic proﬁle of bFGF release. (f) The bioactivity analysis of the
bFGF released from the bFGF-CM complex (
∗P < 0.05,
∗∗P < 0.01).
to evaluate the ischemic hindlimb perfusion at 1, 2, and 4
weeks. Oxygen saturation of hemoglobin was checked by the
hemoglobin absorption spectrum with a spectrometer (GE
Medical Systems Information Technologies) at a wavelength
range from 500 to 620nm by using a clamp probe placed on
both of the animals’ hind feet, the hair of which had been
removed. Measurements were performed in a chamber at
room temperature. The data was calculated by the parameter
ratio of the right foot/left foot in each animal.
2.9. Histological and Immunohistochemical Examination.
The animals were killed at 4 weeks. Samples from the
implanted sites with stitched markers in ischemic muscle
were treated with 10% neutralized formalin, embedded in
paraﬃn, and cut into 4μm sections. The samples in the
ischemic group without treatment were harvested from the
samesitesastheothergroups.Thesectionswerestainedwith
hematoxylin and eosin. The specimens were also immuno-
histochemically stained with an antibody against von
Willebrand factor (vWF; Dako, Carpinteria, CA, USA) to
determine the quantitative capillary density and with an
antismooth muscle α-actin (SMA) antibody (Dako) to eval-
uate the quantitative maturation of arteries. Positive staining
indicated the presence of capillaries or mature vascular
vessels. Vessel densities were calculated as the number of
vessels/mm2.
2.10. Statistical Analysis. Data is expressed as means ± SD.
Analysis of variance (ANOVA) followed by Student’s test
was used to determine the signiﬁcant diﬀerences among the
groups. All data were considered signiﬁcant at P<0.05.
3. Results
3.1. Characterization of the CM and the bFGF-CM Complex.
Both the CM and the bFGF-CM complex were white multi-
porous collagen matrices that look the same from the
scanning electron microscope image and the gross view
(Figure 1(a)).Theaverageporesizewas100μm(Figure 1(b))
with80.2%porosity.TheporesintheCMareinterconnected
(Figure 1(b)). The CM had a high rehydration capacity; the
rehydration ratio reached 2.94 ± 3.4 (Figure 1(d)).
3.2. Cytoxicity of the CM. As shown in Figure 1(c), the pro-
liferation rate of the MSCs cultured with CM particles was
not signiﬁcantly diﬀerent from the control, indicating that



















Figure 2: The oxygen saturation parameter ratio of the right,
operated hindlimb/the left, nonoperated hindlimb at 1, 2, and 4
weeks (
∗∗P < 0.01).
indicated that the eﬀect of toxicity of the crosslinking agent
could be excluded in our study (Figure 1(c)).
3.3. bFGF Releasing Proﬁle. The release of bFGF from the
bFGF-CM complex was constant and sustained, and the
cumulative release increased linearly with time (Figure 1(e)).
By day 10 of the release study, 67.3% ± 2.2% of bFGF was
released to the external medium. The releasing proﬁle
reached the plateau phase by day 8.
3.4. Bioactivity of Released bFGF In Vitro. In order to
determine whether the bFGF incorporated into CM was
inactivated or not, the bioactivity of the released bFGF was
established by assessing its ability to stimulate the expansion
of MSCs in vitro. The results presented in Figure 1(f) reveal
that MSCs cultured in the release media collected on days 2
and 5 showed increased proliferation in vitro compared to
those cultured in control media.
3.5. Oxygen Saturation Analysis in Ischemic Hindlimbs. The
oxygen saturation of hemoglobin was measured at an
equivalent position in hindlimbs that had been operated
on and those that had not. After treatment, the pedal
oxygen saturation (an indicator of extremity perfusion) was
examined at 1, 2, and 4 weeks. In the bFGF-CM group, the
oxygen saturation was 0.7±0.05, 0.85±0.04, and 0.89 ± 0.03
i nw e e k s1 ,2 ,a n d4 ,r e s p e c t i v e l y .T h ep a r a m e t e r sw e r e0 . 6 9
± 0.02, 0.75 ± 0.04, and 0.83 ± 0.01 in the CM group and
0.64 ± 0.07, 0.78 ± 0.04, and 0.82 ± 0.04 in the bFGF group.
In the ischemic group, the oxygen saturation measures were
0.6 ± 0.05, 0.68 ± 0.04, and 0.73 ± 0.03. In all groups,
oxygen perfusion improved gradually with time. However,
in the bFGF-CM group, the oxygen saturation parameters
were signiﬁcantly higher than those in the ischemic, bFGF,
a n dC Mg r o u p sa tw e e k s2a n d4( P<0.01). The oxygen
saturation parameters in the bFGF and CM groups were
signiﬁcantly higher than those in the ischemic group at week
2a n dw e e k4( P<0.01). The oxygen saturation parameters
(a)
(b)
Figure 3: (a) bFGF-CM was being implanted into the ischemic
hindlimb muscle, the implanted sites were stitched as markers
for samples collection. (b) At harvest, ischemic hindlimb tissue
regenerated well; the stitched markers indicated the bFGF-CM
implantation sites.
in the CM group were similar to those in the bFGF group at
the diﬀerent time intervals (P>0.05) (Figure 2).
3.6. Gross View and Histological and Immunohistochemical
Analysis. The bFGF-CM complex was implanted intramus-
cularly (Figure 3(a) showed that the bFGF-CM was being
implanted into the ischemic muscle). After 4 weeks, the
ischemic tissue regenerated well (Figure 3(b)). More vessels
formed in the bFGF-CM group than in the CM, bFGF,
and ischemic groups (Figure 4). The densities (indicated as
vessels/mm2) of capillaries with positive staining for vWF
were 111.2 ± 28.9, 67.8 ± 25.9, 56.6 ± 17.5, and 29.4
± 8.2 in the bFGF-CM, CM, bFGF, and ischemic groups,
respectively. The capillary number in the bFGF-CM group
was signiﬁcantly more than that in the CM and bFGF
groups (P<0.05). The number of capillaries in the CM
and bFGF groups was signiﬁcantly higher than that in
the ischemic control group (P<0.05). The diﬀerence in
capillary number between the CM and bFGF groups was
not signiﬁcant (Figure 5). The number of mature vessels
with positive staining for SMA was signiﬁcantly more inThe Scientiﬁc World Journal 5
(a) (b)
(c) (d)
Figure 4: Hematoxylin-eosin analysis for revascularization in the muscles of the ischemic hindlimb 4 weeks after implantation. (a) No
treatment; (b) bFGF; (c) CM; (d) bFGF-CM (bar = 50μm).
































Figure 5: Immunohistochemical analysis for von Willebrand factor in ischemic hindlimbs 4 weeks after implantation. (a) No treatment; (b)
bFGF; (c) CM; (d) bFGF-CM (bar = 50μm). (e) Histogram of the number of capillaries in the ischemic, bFGF, CM, and bFGF-CM groups
(
∗P < 0.05,
∗∗P < 0.01).6 The Scientiﬁc World Journal
the bFGF-CM group (Figure 6(d)) than that in the CM
(Figure 6(c)), bFGF (Figure 6(b)), and ischemic groups
(Figure 6(a)). The density of mature vessels in the bFGF-
CM group was 30 ± 4.8vessels/mm2, which was signiﬁcantly
higher than that in the CM (22.2 ± 5.7vessels/mm2),
bFGF (20 ± 4.7vessels/mm2), and ischemic groups (7.4 ±
1.5vessels/mm2; P<0.05; Figure 6(e)). The number of ma-
ture vessels in the CM and bFGF groups was signiﬁcantly
higher than that in the control ischemic group (P<0.05).
There was no signiﬁcant diﬀerence between the CM and
bFGF groups (Figure 6).
4. Discussion
In the present study, we demonstrated that spatial and
temporal sustained delivery of bFGF from a CM in a rabbit
model of critical hindlimb ischemia resulted in neovessel
formationandanincreaseinhindlimbperfusion.Therelease
of bFGF from the bFGF-CM complex was sustained for 10
days.Additionally,thebFGFincorporatedintoCMremained
bioactive as demonstrated by the ability to stimulate MSC
proliferationinvitro.TheoxygensaturationinthebFGF-CM
group was signiﬁcantly higher than that in the CM, bFGF
and ischemic groups 2 weeks after the bFGF-CM complex
was implanted. The extent of angiogenesis was determined
by the amount of capillaries and mature vessels that were
positive for antibodies against vWF and SMA, respectively.
The number of capillaries or mature vessels was signiﬁcantly
higher in the bFGF-CM group than that in the CM, bFGF,
and ischemic groups at week 4.
Regeneration therapy using angiogenic cytokines has
shownpromisingresultsforchronicperipheralarterydisease
[16, 17]. Among these cytokines, bFGF is one of the most
potent mitogens for therapeutic angiogenesis [18]. As
chronic ischemic hindlimb needs long-term treatment, a
sustained drug delivery system is urgently needed. The
duration of exposure to bFGF may be a critical determinant
of formation of stable neovasculature [19].
Biosynthetic matrices with bioactive and bioresorbable
characteristics are becoming more important than ever
before [20, 21]. Future biosynthetic matrices should possess
both bioactive and bioresorbable properties to facilitate
tissue regeneration and enhance the replacement of the
matrix itself [22, 23]. Our previous report conﬁrmed that
gelatin microspheres loaded with bFGF improved capillary
formation in the lower extremity compared with bFGF
alone [11]. Therefore in the present study, we used another
common biodegradable material, that is, collagen.
According to previous studies, the collagen biomaterial
hasprominentproperties:ﬁrstly,theporeandporosityofthe
collagen matrix could be controlled [24]; secondly, cytokines
could easily be impregnated into the collagen matrix without
aﬀecting its bioactivity [25]; thirdly, a stable and long-term
sustained release of cytokines from the collagen matrix could
be achieved [25]. Another reason for using a collagen matrix
is based on our prior work in which we demonstrated the
utility of collagen biomaterial for cell attachment and prolif-
eration [26]. Moreover, collagen scaﬀold seeded with bone
marrow-derived MSCs was a stronger angiogenic inducer
than MSCs alone [27]. Collagen can induce proangiogenesis
and provide long-term activation of gelatinase A, which
is likely to be relevant to endothelial cell invasion during
angiogenesis [28]. Our results were consistent with these
studies.
The bFGF was released from the CM over a period of
time and triggered therapeutically signiﬁcant angiogenesis,
including improved hindlimb perfusion and the formation
of capillaries and mature blood vessels. These results suggest
that angiogenesis depends on the sustained release of bFGF.
The study lasted for 4 weeks in order to decrease
the formation of leaky vessels and facilitate the formation
of pericytes or smooth muscle cells indicating the stable
vasculature around endothelial cells [29]. In the bFGF-CM
group, the oxygen saturation, capillary growth, and mature
vessel formation were signiﬁcantly more than those in the
CM, bFGF, and ischemic groups. The percentages of the
mature vessels/the total vessels in bFGF-CM, CM, bFGF,
and ischemic groups were 24.8%, 29.8%, 33.3%, and 23.7%,
respectively. There was more capillaries formation than
mature vessels formation at 4 weeks. We speculated that if
we prolonged the research, more capillaries would become
mature vessels due to the bFGF sustained releasing proﬁle.
The angiogenesis improved the blood ﬂow in ischemic
hindlimbs. This improvement could be due to the release of
bFGF at the ischemic site at the correct time for facilitation
of therapeutic angiogenesis. Sustained release of bFGF may
facilitate endothelial cell, smooth muscle cell, or pericyte
recruitment resulting in the formation of stable, mature
vasculature [30, 31].
The localized, timely, and sustained delivery of the
growth factor used in this study enabled the control of
therapeutic angiogenesis [32]. Additionally, using the system
developed in this study we demonstrated that controlled
delivery of bFGF could result in an increased growth and
maturation of vessels as shown by immunohistochemical
staining. Previous studies using bolus injections of growth
factors had minimal success in sustaining mature vessel
density and hindlimb blood ﬂow because of the short half-
life of common angiogenic growth factors [2]. The mature
vessels induced by sustained delivery did not appear to
regress, as indicated by the number of vessels [33].
In future clinical applications, doctors have to carefully
consider the sites and ways of using the bFGF-CM complex
for transplantation in patients with ischemic hindlimbs
disorders. There are some diﬀerences between human beings
suﬀering from ischemic hindlimb disorders and ischemic
hindlimb animal models. In the human body, the arteries
are narrowed or occluded, but they are present. However, in
animal models, the arteries are removed. Therefore, accord-
ing to our experience, the bFGF-CM should be implanted
along the sides of the occluded artery to stimulate angiogen-
esis, which could connect the proximal and distal parts of the
occluded artery and allow more blood supply and perfusion
into the extremity. The ways of application of the bFGF-
CM could be adjusted according to the condition; the bFGF-
CM complex could be used in small pieces via injection orThe Scientiﬁc World Journal 7






























Figure 6: Immunohistochemical analysis for smooth muscle α-actin in ischemic hindlimbs 4 weeks after implantation. (a) No treatment;




implanted in bulk (e.g., as a disc, similar to what we used in
this study (Figure 3)d u r i n gas u r g e r y .
In conclusion, a complex composed of bFGF and
multiporous CM was fabricated. This system showed no
toxicity and ideal biocompatibility both in vivo and in vitro.
Once implanted, the bFGF-CM complex showed higher ef-
ﬁcacy in improving lower extremity perfusion, capillary
density, and mature vasculature formation compared with
the control groups in the chronic ischemic hindlimb model.
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